• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

临床试验中疗效和毒性反应监测指南。

Guidelines for monitoring efficacy and toxicity responses in clinical trials.

作者信息

Cook R J, Farewell V T

机构信息

Department of Statistics and Actuarial Science, University of Waterloo, Canada.

出版信息

Biometrics. 1994 Dec;50(4):1146-52.

PMID:7786995
Abstract

There is currently a need for clinical trial methodology that allows formal consideration of toxicity responses. Since a complete evaluation of an experimental therapy addresses both relative efficacy and relative toxicity, general methods for handling bivariate response data are of interest. A procedure for sequentially analysing both efficacy and toxicity data is presented. The procedure is designed to allow early termination due to efficacy results, toxicity results, or both. The method is based on modified marginal sequential analyses, accounting for bivariate correlated responses and multiple analyses over time. The theory is presented in the context of normally distributed responses. Extensions to bivariate failure time data are indicated and an example from a kidney transplant study demonstrates the procedure.

摘要

目前需要一种临床试验方法,以便能够正式考虑毒性反应。由于对一种实验性疗法的全面评估既要涉及相对疗效,也要涉及相对毒性,因此处理双变量反应数据的通用方法备受关注。本文提出了一种对疗效和毒性数据进行序贯分析的程序。该程序旨在允许因疗效结果、毒性结果或两者而提前终止试验。该方法基于修正的边际序贯分析,考虑了双变量相关反应以及随时间的多次分析。该理论是在正态分布反应的背景下提出的。文中指出了对双变量失效时间数据的扩展,并且来自肾移植研究的一个例子展示了该程序。

相似文献

1
Guidelines for monitoring efficacy and toxicity responses in clinical trials.临床试验中疗效和毒性反应监测指南。
Biometrics. 1994 Dec;50(4):1146-52.
2
An adaptive approach to implementing bivariate group sequential clinical trial designs.一种实施双变量组序贯临床试验设计的自适应方法。
J Biopharm Stat. 2003 Nov;13(4):605-19. doi: 10.1081/BIP-120024197.
3
Group sequential tests for bivariate response: interim analyses of clinical trials with both efficacy and safety endpoints.双变量反应的序贯检验:具有疗效和安全性终点的临床试验的期中分析。
Biometrics. 1993 Sep;49(3):741-52.
4
Stopping a clinical trial very early based on unplanned interim analyses: a group sequential approach.基于非计划的期中分析提前终止临床试验:一种序贯设计方法。
Biometrics. 1995 Sep;51(3):1152-62.
5
Global cross-ratio models for bivariate, discrete, ordered responses.用于双变量、离散、有序响应的全局交比模型。
Biometrics. 1986 Dec;42(4):909-17.
6
Study duration for clinical trials with survival response and early stopping rule.具有生存反应和早期终止规则的临床试验的研究持续时间。
Biometrics. 1990 Mar;46(1):81-92.
7
A decision rule for sequential monitoring of clinical trials with a primary and supportive outcome.一项用于对具有主要和支持性结局的临床试验进行序贯监测的决策规则。
Clin Trials. 2007;4(2):140-53. doi: 10.1177/1740774507076936.
8
Robust tests for treatment comparisons based on recurrent event responses.基于复发事件反应的治疗比较的稳健检验。
Biometrics. 1996 Jun;52(2):557-71.
9
Bayesian monitoring of clinical trials with failure-time endpoints.具有失效时间终点的临床试验的贝叶斯监测。
Biometrics. 2005 Mar;61(1):239-45. doi: 10.1111/j.0006-341X.2005.031037.x.
10
Continuous toxicity monitoring in phase II trials in oncology.肿瘤学II期试验中的连续毒性监测
Biometrics. 2005 Jun;61(2):540-5. doi: 10.1111/j.1541-0420.2005.00311.x.

引用本文的文献

1
Inheritance of paternal lifestyles and exposures through sperm DNA methylation.通过精子 DNA 甲基化遗传父系生活方式和暴露。
Nat Rev Urol. 2023 Jun;20(6):356-370. doi: 10.1038/s41585-022-00708-9. Epub 2023 Jan 18.
2
Group-sequential logrank methods for trial designs using bivariate non-competing event-time outcomes.基于二元非竞争事件时间结局的试验设计的分组序贯对数秩检验方法。
Lifetime Data Anal. 2020 Apr;26(2):266-291. doi: 10.1007/s10985-019-09470-4. Epub 2019 Apr 12.
3
Design, data monitoring, and analysis of clinical trials with co-primary endpoints: A review.
具有共同主要终点的临床试验的设计、数据监测与分析:综述
J Biopharm Stat. 2018;28(1):28-51. doi: 10.1080/10543406.2017.1378668. Epub 2017 Oct 30.
4
Choice of futility boundaries for group sequential designs with two endpoints.具有两个终点的序贯设计中无效性边界的选择。
BMC Med Res Methodol. 2017 Aug 8;17(1):119. doi: 10.1186/s12874-017-0387-4.
5
Interim evaluation of efficacy or futility in group-sequential trials with multiple co-primary endpoints.具有多个共同主要终点的序贯分组试验中疗效或无效性的中期评估。
Biom J. 2017 Jul;59(4):703-731. doi: 10.1002/bimj.201600026. Epub 2016 Oct 19.
6
A Rejection Principle for Sequential Tests of Multiple Hypotheses Controlling Familywise Error Rates.一种用于控制族系错误率的多重假设序贯检验的拒绝原则。
Scand Stat Theory Appl. 2016 Mar 1;31(1):3-19. doi: 10.1111/sjos.12161. Epub 2015 May 25.
7
Assessing the impact of safety monitoring on the efficacy analysis in large Phase III group sequential trials with non-trivial safety event rate.评估在具有显著安全事件发生率的大型III期成组序贯试验中,安全性监测对疗效分析的影响。
J Biopharm Stat. 2016;26(4):672-85. doi: 10.1080/10543406.2015.1052473. Epub 2015 May 26.
8
Sequential Tests of Multiple Hypotheses Controlling Type I and II Familywise Error Rates.控制I型和II型家族性错误率的多重假设序贯检验。
J Stat Plan Inference. 2014 Oct 1;153:100-114. doi: 10.1016/j.jspi.2014.05.010.
9
Adjustment on the Type I Error Rate for a Clinical Trial Monitoring for both Intermediate and Primary Endpoints.针对中期和主要终点的临床试验监测的I型错误率调整
J Biom Biostat. 2012 May 19;7:15. doi: 10.4172/2155-6180.S7-015.
10
Monitoring futility in a two-by-two factorial design: the SPS3 experience.在二乘二析因设计中监测无效性:SPS3 经验。
Clin Trials. 2013 Apr;10(2):250-6. doi: 10.1177/1740774512474374. Epub 2013 Feb 1.